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1. Introduction 
Japanese encephalitis virus (JEV) is a flavivirus that is one of the major causes of encephalitis 
in Eastern and Southern Asia with recent observations marking its spread to newer 
geographical regions. Flaviviruses, in general consitutute a global health threat since many 
of them are endemic in large parts of the Americas, Africa and Australia in addition to Asia 
and suitable vaccines are unavailable for many of them. JEV causes serious inflammation of 
the brain, which may lead to permanent brain damage, and has a high mortality rate. More 
than three billion people live in JE endemic areas and JEV is estimated to cause 45,000 
human cases of disease and 10000 deaths per year (Solomon and Winter, 2004; van den 
Hurk et al., 2009). 
The occurrence of encephalitic epidemics in humans due to this virus have been recognized 
from 1870s in Japan where it was termed Japanese B encephalitis to distinguish it from type 
A encephalitis caused by sleeping sickness. The first prototype Nakayama strain was 
isolated and established in 1935 from the brain of a fatal case from Tokyo, Japan. This was 
closely followed by virus isolation from Culex tritaeniorrhynchus in 1936 confirming earlier 
suspicions that mosquitoes served as the transmission vector (Solomon et al., 2000). 
JEV transmission occurs through a zoonotic cycle involving mosquitoes as an important 
intermediate maintenance and replicative vector. Vertebrates, chiefly pigs and ardeid birds 
act as amplifying hosts. Only those animals that develop high viraemias are significant in 
this natural enzootic cycle. Humans are infected only coincidently when bitten by an 
infected mosquito and are dead end hosts. Human to human transmission is yet to be 
documented, possibly due to the presence of transient viraemia. The absence of high serum 
viraemia prevents the virus from being picked up during mosquito bites. Pigs play a major 
role in the transmission cycle with respect to human infection since they are often bred close 
to humans whereas herons, egrets and other ardeid birds are important for maintenance and 
overwintering of this virus. Among the other vertebrates, horses also develop central 
nervous system (CNS) infections and are considered as dead end hosts. Rodents are 
relatively refractory to infections while amphibians, reptiles and bats can also be infected 
(Mackenzie et al., 2004). JEV does not cause encephalitis in pigs and birds although it is 
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known to result in abortions in pigs (D.S. Burke and Leake, 1988). Thus the incidence of JEV 
induced disease correlates with rising mosquito densities and increased human contact with 
amplifying vertebrate hosts. As a result, activities such as deforestation and irrigation that 
are associated with farming as well as increases in temperatures and precipitation that 
occurs during monsoons favor JEV infection and propagation. Not surprisingly, seasonal 
JEV epidemics are associated in the tropics with the beginning of the monsoon season 
(Umenai et al., 1985). The increased rainfall during the monsoon season has been shown to be 
followed by an increase in mosquito breeding leading to seroconversion in farm animals and 
later human encephalitis (Mani et al., 1991) in Southern India as well as in other northern areas 
of Vietnam, Thailand and Korea, Japan and China (Erlanger et al., 2009; Hoke et al., 1988). 
Under laboratory conditions Culex species Cx. tritaeniorrhynchus, Cx. geldius, Cx. 
pseudovishnui and Cx. fuscocephala have found to be very efficient vectors for JEV 
transmission (Solomon, 2006; Solomon, 2004). However, JEV has also been isolated from 
other species of mosquitoes as well. JEV has been isolated from ten different species of 
Culex, four different species of Anopheles and three different species of Mansonia mosquitoes 
(Reuben and Gajanana, 1977). Among various Culex species, Cx. tritaeniorrhychus has been 
found to be a very efficient vector for JEV replication and transmission. It breeds 
predominantly in paddy fields and is the primary vector for transmission of JEV throughout 
Southeast Asia (Takahashi, 1976).  
2. Epidemiology 
A major epidemic involving encephalitis was observed in Japan in 1924 with over 6000 cases 
and 3797 deaths which was followed by another large outbreak in 1935 and then, annual 
outbreaks from 1946 to 1952. Subsequently, outbreaks were reported in China in 1940 and in 
Korea in 1949 and in other Asian countries which include Thailand, Vietnam, Burma, 
Bangladesh, Indonesia, Malaysia, the Philippines, Sri Lanka, India, and Taiwan where 
epidemics have been reported since 1950s. JE was reported from Russia in 1938 while a large 
epidemic was reported in North Vietnam and North Thailand in the 1960s (Endy and 
Nisalak, 2002). 
JE is now being described from newer geographical areas and was reported from Australian 
Torres straits island as well as the mainland in 1995 and 1998 (Mackenzie et al., 2002; Hanna 
et al., 1999). The factors contributing to this geographical spread could be multifold 
including several environmental and ecological factors as well as the ability of humans to 
travel and birds to migrate. The former was exemplified by the isolation of another 
flavivirus, WNV from New York in 1999 (Lanciotti et al., 1999).  
In India, JEV was first diagnosed in 1955 in Vellore, North Arcot district of Tamil Nadu 
(Kabilan et al., 2004). Major outbreaks were reported in West Bengal in 1973 with 700 cases 
and 300 deaths. This was followed by another epidemic in 1976 in the same region. Other 
outbreaks have been reported in several other states of India which include Bihar, Andhra 
Pradesh, Assam, Manipur, Uttar Pradesh, Karnataka, Madhya Pradesh, Maharashtra and 
Haryana (Kabilan et al., 2004). 
Broadly three epidemiological regions have been associated with JE (Rodhain, 1996): 
1. Temperate epidemic region: In temperate regions such as Northern China, Korea, 
Japan, Taiwan and Southern Russia, the extreme low temperatures of the winters do not 
allow mosquito transmission. However, in the summer and autumn months, the thaw 
and increase in temperatures allows mosquito transmission, possibly leading to large 
epidemics. 
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2. Endemic region: In southern regions of India, Southern Vietnam, Thailand, the 
Phillipines, Malayasia and Indonesia, JEV is endemic due to the constant presence of 
mosquitoes and the bird-mosquito-pig cycle gains predominance. 
3. Intermediate subtropical region: In Northern India, Burma, Northern Thailand, 
Northern Vietnam and Southern China and Bangladesh, JEV transmission occurs 
continuously at low levels. However, it increases soon after the monsoon and rainy 
season. Unexposed children are mostly affected in such regions since the adults in the 
region would have been exposed at some time to the virus. 
JEV causes disease mostly in new born children and young adults. Most infections in adults 
are asymptomatic, at most having flu-like symptoms and rarely cause disease. However, 
immunologically naïve adults are susceptible to the disease and they could be affected when 
epidemics occur for the first time in their geographical area. The estimated ratio of 
symptomatic to asymptomatic infection varies from 1 in 25 to 1 in 1000 (Solomon and Winter, 
2004). The incidence of symptomatic JE infection is influenced by several factors including 
previous exposure to flaviviruses, age-related differences, different immunological and genetic 
factors as well as efficiency of available surveillance procedures. The occurrence of high levels 
of neutralizing antibodies in children aged above 14 years, possibly due to natural exposure 
and subclinical infections decreases the susceptibility of these older age groups. 
3. Clinical features 
JEV normally infects children below 15 years and man to man transmission of JEV is not 
detected. The incubation period after the infected mosquito bite is not exactly known, but 
varies from 1-6 days normally. The onset of illness can be abrupt, acute, subacute or gradual. 
Progression of disease can be divided into three stages: (i) the prodromal stage preceding 
CNS features (ii) an encephalitis stage marked by CNS symptoms and (iii) the late stage 
noticeable by recovery or persistence of signs of CNS injury (Misra and Kalita, 2010; Huy et 
al., 1994; Kumar et al., 1993). Definitive clinical diagnosis is not possible in prodromal stage, 
but is characterized by high grade fever, with or without rigors, headache, general malaise, 
nausea and vomiting. The prodromal stage usually lasts 1-6 days. It can be as short as less 
than 24 hr or as long as 14 days. The initial symptoms in children are usually nausea, 
vomiting and abdominal pains that are associated with acute abdominal syndromes. The 
encephalitic stage is characterized by altered sensorium, convulsions, neck stiffness, 
muscular rigidity and abnormal movements, speech impairment, mask-like face, tremors in 
finger, eyes, eyelids and tongue. The late stage is characterized by the persistent signs of 
CNS injury such as mental impairment, increased deep tendon reflexes, paresis either of the 
upper or lower motor neuron type, epilepsy, abnormal movements and behavioral 
abnormalities. Case fatality rates for JEV range from 0-30% (Burke et al., 1985). Children 
who survive take several weeks to regain the neurological functions. However, only one 
third of the affected children recover the normal neurological functions. 30% of survivors 
have persistent motor deficits like weakness of upper and lower motor neurons. 20% of the 
patients suffer from severe cognitive and language impairment and some patients show 
further convulsions. Some patients are observed to exhibit mild sequelae such as learning 
disabilities and behavioral problems (Kumar et al., 1993). Chronic progressive encephalitis 
and relapse, caused by persistence of virus in the CNS has been reported in a small number 
of patients (Pradhan et al., 2001; Ravi et al., 1993). The details involving the clinical 
presentation of JE have been reviewed (Misra and Kalita, 2010). 
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4. Structural and genome organization 
4.1 RNA genome 
JEV is a RNA virus belonging to the Flavivirus genus of the family Flaviviridae. The 
Flaviviridae is a large family of viruses responsible for causing severe disease and mortality 
in humans and animals. The family consists of three genera: Flavivirus, Pestivirus and 
Hepacivirus. Among the three, Flavivirus is the largest genus and includes several viruses 
including dengue virus (DNV), Japanese encephalitis virus (JEV), tick-borne encephalitis 
virus (TBEV), West Nile virus (WNV) and yellow fever virus (YFV). Most members of the 
Flavivirus genus are arthropod-borne or arboviruses, which indicates the requirement of a 
blood sucking arthropod to complete their life cycle. Few of the members have no known 
vector. The genus contains over 70 viruses, of which approximately 40 are mosquito borne, 
16 are tick borne and 18 have no known vector (Heinz et al., 2000). Flaviviruses are 
serologically related and are classified based on cross-neutralization assays using polyclonal 
sera into 12 sero-complexes (D.S Burke and Monath, 2001; Gubler, 2002). The important ones 
are the dengue serological group, Japanese encephalitis serological group and yellow fever 
virus group. JEV belongs to the JE serocomplex which also includes St. Louis encephalitis virus 
(SLE), West Nile Virus (WNV), Kunjin virus (KUNV), Murray Valley encephalitis virus 
(MVEV), Cacipacore virus (CPCV), Kautango virus (LOUV), Alfuy virus (ALFV), Usutu virus 
(USUV) and Yaounde virus (YAOV). JEV has been grouped into 5 genotypes (I -V) based on 
the phylogenetic analysis of PrM and E encoding genes and different genotypes are found in 
different climatic regions (Heinz et al., 2000; Nitatpattana et al., 2008; Solomon, 2006).  
The complete nucleotide sequence of JEV was reported in 1990 (McMinn, 1997) and shows that 
it consists of a single stranded, positive-polarity 11kb long RNA. The 3’ end of the genome 
lacks a poly-A-tail and a type 1 cap (m7GpppAmp) is found at the 5’ end. Flaviviral genome 
RNAs are also characterized by their high purine content and low CG and UA doublet 
frequencies (Rice et al., 1985). Untranslated regions (UTR) that contain highly conserved 
sequences and secondary structures are located at the 5’ and 3’ end of the JEV genome and are 
95 and 585 nucleotides long respectively (Sumiyoshi et al., 1987). Host cell and viral proteins 
are involved in the conversion of the positive sense RNA into a negative sense RNA through a 
double stranded replicative form (dsRF) after the first round of translation. The negative sense 
RNA acts as a template for the synthesis of progeny positive sense RNAs that is packaged with 
viral proteins and assembled into infectious virus particles. Approximately 10-100 fold excess 
plus strands exist relative to negative strands at any given time within an infected cell. Several 
cellular and viral proteins such as EF-1ǂ (Davis et al., 2007), TIA-1 (Li et al., 2002) and YB-1 
(Paranjape and Harris, 2007) have been reported to bind the UTRs and regulate flaviviral 
translation and replication. In the case of JEV, FBP1 represses JEV protein expression by 
interacting with the 3’ and 5’ UTRs (Chien et al., 2011) and La autoantigen facilitates 
replication by interacting with the 3’ UTR. The role of various host cell factors in flaviviral 
infection and replication has been reviewed in detail elsewhere (Pastorino et al., 2010). 
The RNA genome of JEV contains a single long open reading frame that codes for a 
polyprotein which is cleaved by host and viral encoded proteases to form three structural 
and seven non-structural proteins (Fig 1). The N-terminal end of the polyprotein encodes 
the three structural proteins called capsid (C), a glycosylated membrane protein precursor 
(prM) and an envelope protein (E). The prM is cleaved to precursor (pr) and membrane 
protein (M) during JEV maturation. These structural proteins are followed by seven non-
structural (NS) proteins (NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) (Chambers et al., 1990). 
The structural proteins finally become components of the mature infectious viral particle 
www.intechopen.com
 
Japanese Encephalitis Virus: Innate and Adaptive Immunity 
 
343 
while the non-structural proteins take part in the process of polyprotein processing, viral 
RNA synthesis and virus morphogenesis within the infected cell. Signal sequences direct the 
polyprotein precursor into the host endoplasmic reticulum (ER) with NS1 and the 
exogenous domains of prM and E facing the lumen while C, NS3 and NS5 are cytoplasmic. 
The mature viral proteins are formed by post and cotranslational cleavage of the 
polyprotein by NS3 in the cytoplasm and ER resident host proteases. Both the processes of 
polyprotein processing and RNA replication are thought to occur in distinct but adjacent 
compartments composed of convoluted membranes and vesicle packets containing dsRNA 
(Salonen et al., 2005; Welsch et al., 2009). The process of virus assembly occurs in the lumen 
of the rough endoplasmic reticulum (RER) while the final maturation of virus particles 
occurs in the trans-golgi network and involves the cleavage of prM to M by furin-like 
protease. This is a step that causes conformational rearrangements of the E protein and is 
essential for converting fusion incompetent, non-infectious virus particles to mature infectious 
virions (Yu et al., 2008). These mature viruses exit the host cell as packages of virions. 
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Fig. 1. Schematic diagram of Japanese encephalitis virus genome and polyprotein 
organization. 11 kb ssRNA JEV genome can be divided into four regions – 5’Cap and 5’UTR, 
Structural Protein coding gene regions, Nonstructural Protein coding gene regions and 
3’UTR. It codes for ~ 380 kDa polyprotein which is further processed by several host and 
viral proteases to give rise to individual proteins. These individual proteins can assemble 
together to give rise to structural complexes made up of capsid (C), matrix (M) and envelope 
(E) proteins. The nonstructural proteins take part in virus replication and assembly within 
infected cells but do not form part of the mature virus particle that is released (adapted from 
Assenberg et al., J. Virol (2009) 83: 12895-12906 
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The RNA genome is packed into a particle by the viral capsid protein (C) in a host-derived 
lipid bilayer containing the viral envelope protein (E) that participates in receptor binding, 
membrane fusion and viral assembly. The virus gains access to local fibroblasts when it is 
deposited at a local site during the mosquito bite where it replicates leading to transient 
serum viraemia. Both hsp70 (Das et al., 2009b) and integrin molecules (Chu and Ng, 2004) 
have been shown to act as viral receptors for JEV and WNV respectively. Subsequent viral 
entry occurs by receptor mediated endocytosis (Lee et al., 2008) involving clathrin coated 
vesicles (Nawa et al., 2003). Low endosomal pH induces a structural reorganization of the E 
protein and mediates the fusion of the viral and host cell membranes resulting in the release 
of the viral nucleocapsid into the cytoplasm (Rey et al., 1995). Infectious virus is released 12 
hrs post infection (p.i.) as studied in infected cell lines but viral RNA synthesis can be 
observed as early as 3 hrs after infection and host macromolecular synthesis is not 
significantly inhibited by the virus at these times. Although a wide variety of host cells 
including arthropod cells support virus infection, monocytes, macrophages and dendritic 
cells are believed to be the main cells that support the spread of this virus into the visceral 
organs and thence into the CNS in vertebrates. Maximum virus titres vary considerably 
from cell type to cell type. Although the virus infections in arthropod cells are generally 
noncytopathic, they are cytocidal in vertebrate cells (Chambers et al., 1990). The period of 
transient viraemia is followed by the viral invasion of the CNS either through hematogenous 
spread or by the breakage of the blood-brain barrier and entry through endothelial cells in the 
cerebrum (Liu et al., 2008). CNS infection is associated with perivascular cuffing that is rich in 
B cells and the infected parenchyma is invaded by inflammatory macrophages that enter to 
phagocytose infected and dying cells. Parenchymal damage associated with JEV infection is 
mainly due to the inflammatory reactions triggered by such invading leukocytes as well as the 
direct virus- induced cellular apoptotic processes that occur within the CNS. 
4.2 Viral proteins 
4.2.1 The Capsid and matrix protein 
The C protein is highly basic in nature and forms the nucleocapsid along with the genomic 
RNA. The C protein is a small (12-14 kDa) highly positively charged protein that contains a 
C-terminal hydrophobic region that is preceded by a hydrophilic region and a central 
hydrophobic region. It is known to have both N-terminal and C-terminal modifications 
(Chambers et al., 1990). Cathepsin L mediated processing of this protein has been shown to 
play an important role in JEV replication in neural and macrophage cells (Mori et al., 2007). 
Monoclonal antibodies that have been made to the Dengue 4 virus C protein have been 
shown to localize in the nucleus of the infected cell (Tadano et al., 1989) and nuclear 
localization of C has been shown to enhance JEV replication in infected cells (Mori et al., 
2005). The prM (~26 kDa) is a glycoprotein precursor to the M structural protein and 
possesses several N-linked glycosylation sites that are conserved in the JE serogroup while 
the N terminal ‘pr’ segment contains six conserved cysteine residues, all of which form 
disulfide bridges (Chambers et al., 1990). A single N-linked glycosylation site has been 
identified on prM that is essential for the release of JE virus particles from infected cells as 
well as its ability to cause pathogenesis (Kim et al., 2008). A valine to alanine change at aa76 
has been associated with escape from antibody neutralization in MVE (McMinn et al., 1995). 
Anti-prM antibodies were shown to have low virus-neutralizing activity (Takegami et al., 
1982) but its biological significance has not been elucidated. The role of C protein in eliciting 
B cell responses is yet unclear. 
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4.2.2 The envelope protein 
The envelope (E) protein (~ 53 kDa) is the major virion surface protein with 180 copies 
existing as head to tail dimers on the virus surface as shown for Dengue viruses (Kuhn et al., 
2002). It contains about 500 amino acids and two potential glycosylation sites and mediates 
viral attachment and fusion to cell membranes of receptor-bearing cells. These properties of 
E protein are responsible for its glycosylation as well as generating virus neutralizing, 
haemagglutination inhibiting and fusion blocking antibodies. A feature that distinguishes 
this structure from that of many others is that the orientation of the E-head to tail 
homodimers is parallel rather than perpendicular to the membrane as would be expected of a 
viral glycoprotein spike (Heinz and Allison, 2000). The formation of the E protein homodimer 
found in the mature virus particle takes place just before the release of the mature virus 
particle and is associated with the cleavage of the closely associated prM protein to M by a 
furin-like protease (Yu et al., 2008). While the immunogenicity of the flaviviral E protein has 
led to the generation of many monoclonal antibodies that were used to understand virus 
structure, they have also been used to evaluate antigenic drift of related viruses, analysis of 
the replication cycle as well as in virus detection and diagnostic tools (Roehrig, 2003).  
The crystal structure of E protein of JEV has been deduced from knowledge based 
homology modeling approach using 2Å crystal structure of the E protein of TBEV (Rey et 
al., 1995) as template (Kolaskar and Kulkarni-Kale, 1999) as well as recombinant subviral 
particles (RSPs). The RSPs were found to be icosahedral with 30 dimers arranged in a T=1 
lattice. Lateral dimer-dimer interactions appear to involve contacts between a loop in 
domain II on one side and a groove in domains I and III on the other side. The crystal 
structure of E protein of the Dengue virus type 2 S1 strain has also been found to be nearly 
identical to that of TBEV protein (Modis et al., 2003). In addition, all of the 12 cysteines 
present in TBEV and the six disulfide bonds assigned to them are absolutely conserved. 
Three distinct domains (I, II, III) were elucidated in the E protein and this structure has been 
assumed for all flavivirus E proteins. These domains directly correspond to the antigenic 
domains C, A and B respectively, which had been previously defined using monoclonal 
antibodies to examine the antigenic structure of the TBEV envelope protein. Based on the E 
protein model of Kolaskar and Kulkarni (1999), domain I contains 128 amino acid residues 
from 1-51,137-196 and 293-311. The second domain (II) consists of 171 amino acid residues 
from 52-136 and 197-292 and the IIIrd domain is a contiguous stretch of 100 amino acid 
residues from 310-411. Domain III contains an IgC immunoglobulin-like domain (Lin and 
Wu, 2003), that is a unique feature not found in other viral envelopes and an integrin 
binding motif RGD at aa387-389. This integrin binding motif has been suggested to be 
involved in viral attachment to the target cell (Mandl et al., 2000; Rey et al., 1995) while 
amino acids 98-110 of domain II has been suggested to form a barrel shaped fusion peptide 
that is responsible for initiating the fusion of the virus to endosomal target membranes 
(Allison et al., 2001; Rey et al., 1995). A unique transmembrane hairpin present in the E 
protein is needed for this membrane fusion event (Fritz et al., 2011). Recently, a broadly 
flavivirus cross-neutralizing epitope has been characterized within this fusion loop (Deng et 
al., 2011). Thus, many of the JEV neutralizing epitopes/regions have been found in these 
two domains with predominance in Domain III (Table 1). Peptides from this region have 
also been useful for serological diagnosis (Chavez et al., 2010). However, the binding site of 
a strongly neutralizing monoclonal antibody (mAb) against JEV (Kimura-Kuroda and Yasui, 
1983) was shown to be at the junction area of the Domain I and II and being distant from the 
virus-target cell attachment site (Morita et al., 2001). Several neutralizing antibodies have 
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been shown to bind the C-terminal E region aa280-414 (Mason et al., 1987). Fragment (aa205-
456) that was obtained by CNBr cleavage of the purified E protein has also been shown to 
induce neutralizing antibodies (Srivastava et al., 1990). Overall, six neutralization regions 
have been identified based on escape variant analysis of different flaviviruses including JEV. 
These are region 1, aa66-72 and 112; region 2, aa123-128; region 3, aa155 and 158; region 4, 
aa171, 181 and 293, region 5, aa52, 136 and 270 -279; region 6, aa307-311, 333 and 384-385. 
These regions are found on the outer, upper or lateral surfaces of the E-glycoprotein. Many 
of these regions of the E protein that are associated with neutralizing epitopes have been 
used in various immunization approaches to develop vaccines and have been detailed later 
in the chapter. 
 
Envelope 
Domain 
Amino Acid 
Number 
Property of neutralization epitope/region Reference 
I, III 303-396 Binds several anti-JEV neutralizing antibodies (Mason et al., 1989) 
II, III 
III 
205-456
375-457 
Fragments obtained by CNBr cleavage
Induces neutralizing antibodies in mice 
(Srivastava et al., 
1990) 
III 319-500 
Protein A fusion protein eluted from 
electrophoretic gels induces neutralizing 
antibodies and protection in mice 
(Srivastava et al., 
1991) 
II 
III 
270
333
Monoclonal antibody neutralization 
escape variant
(Cecilia and Gould, 
1991) 
III 
III 
373-500 
373-399 
Protein A or GST fusion peptide induces 
neutralizing antibodies 
(Seif, Morita, and 
Igarashi, 1996; Seif et 
al., 1995) 
II 
II 
II 
II 
52
126 
136 
275
Monoclonal antibody neutralization 
escape variant (Morita et al., 2001) 
I 149-163 Monoclonal antibody raised to synthetic peptide E149-163 neutralizes JEV 
(Dewasthaly et al., 
2001) 
I 
II 
III 
307-309
327-333 
386-390 
Phage-display libraries used to select 
neutralizing peptide ligands (Wu et al., 2004) 
I, III 292-500 Purified E292-500 induces neutralizing antibodies and protects in mice (Chia et al., 2001) 
III 373-399 
E373-399 expressed as a fusion protein 
with JGM virus like particles induce 
neutralizing antibodies and protection in 
mice
(Saini and Vrati, 2003) 
Table 1. Some Neutralization Epitopes/Regions in the E protein of JEV 
4.2.3 The NS1 protein 
NS1 is a secreted glycoprotein that is highly conserved across flaviviruses and has been 
hypothesized to aid in immune evasion. Flaviviral NS1 has been shown to inhibit 
complement activation both in solution and on cell surfaces (Chung et al., 2006a) due to its 
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ability to bind and recruit the complement regulatory protein factor H. The protein is highly 
immunogenic and some studies report the protective nature of anti-NS1 antibodies both by 
immunization and passive transfer (Chung et al., 2006b; Schlesinger et al., 1986). The NS1 
protein is not incorporated into the mature virion and has been found in the serum of 
infected individuals and animals (Alcon et al., 2002) but its high immunogenicity, serotype-
specific nature of the antibodies and the identification of a conserved B cell epitope on NS1 
of JEV suggests that NS1 is a virus-specific serological antigen (Wang et al., 2009). 
Monoclonal antibodies have been used to define antigenic domains at the N and C- termini 
of JEV NS1. Antibody-based assays using anti-NS1 antibodies have also been designed to 
differentiate between JEV and WNV infections (Kitai et al., 2011). 
Multiple forms of NS1 are present in flavivirus infected cells and a protein containing NS1 
and a portion of NS2A (NS1’) is found within cells and extracellular fluid of JEV infected 
cells. The membrane associated forms are hypothesized to form during its dimerization and 
are detected after 30 minutes of viral protein synthesis (Chambers et al., 1990). It has been 
shown to be a GPI anchored protein (Jacobs et al., 2000; Winkler et al., 1989) and the GPI 
anchor is believed to be added to the C-terminus by an ER resident enzyme. 
The JE serocomplex NS1 contains 12 conserved cysteines that form disulfide bonds and 
three N-linked glycosylation sites. Two of these sites are conserved in all mosquito-borne 
flaviviruses and correspondingly, at least two N-linked oligosaccharide chains are present in 
the cell-associated and extracellular NS1 and NS1’ in JEV infected cells. Mutations in these 
N-linked glycosylation sites led to significant defects in RNA replication indicating its 
important role in virus replication (Chambers et al., 1990). 
NS1 (48 kDa) induces a strong antibody response due to its presence both on the surface as 
well as in secretory form, apart from being present intracellularly in virus induced vesicle 
packets (Fan and Mason, 1990) and extracellular nonvirion forms. This ability of NS1 to 
induce a strong antibody response prompted its evaluation for protective efficacy in mice 
models immunized with either recombinant vaccinia virus (VACV) expressing the NS1 gene 
or recombinant DNA based immunizations (Lin et al., 1998; Konishi et al., 1991). These 
results indicate that immunizations with NS1 can provide only low protection from JEV 
infection, as compared to that elicited by the E protein alone. The secreted form has been 
named as the soluble complement fixing (SCF) antigen due to its ability to fix complement 
(Brandt et al., 1970). A recent study has shown that the E. coli expressed NS1 protein induces 
protective humoral immune response in mice during JEV infection (Lin et al., 2008b). A 
synthetic NS1 peptide has been shown to reconstitute lysis of uninfected syngeneic targets 
by anti-JEV specific CTL (Murali-Krishna et al., 1996) and anti NS1 antibodies have been 
shown to reduce virus production from infected cells (Krishna et al., 2009).  
4.2.4 The NS2A & NS2B protein 
The NS2 protein has two relatively hydrophobic components – NS2A (~25 kDa) and NS2B 
(~16 kDa) with short hydrophilic segments. NS2A forms part of the replication complex, 
inhibits IFN production (Liu et al., 2006a) and is also involved in the biogenesis of Kunjin 
virus-induced membranes that take part in virus assembly (Leung et al., 2008). It has also 
been shown to bind to the 3’ UTR of viral RNA (Mackenzie et al., 1998). Little information is 
available regarding NS2A from JEV, but studies with YFV and KUNV suggests that this 
membrane spanning protein is generated when NS1-2A is cleaved by an ER resident 
protease at the N-terminal end while its C-terminus is generated by virus encoded NS3 
serine protease in the cytoplasm (Falgout and Markoff, 1995). Mutants that block the latter 
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cleavage as well as immunogold localization studies suggest an important role for NS2A in 
virus replication. Mutations at Lys190 of NS2A and other suppressor mutations in NS3 
suggest that NS2A interacts with NS3 in infectious particle production. Similarly, the NS2B 
protein also complexes with NS3 and is a required cofactor for NS3 serine protease activity 
as well as its proper folding. NS2B has also been suggested to modulate membrane 
permeability during JEV infection. Very little information is available regarding their 
antigenic structure but other studies suggest that NS2A and NS2B may take part in viral 
RNA assembly (Leung et al., 2008; Lindenbach and Rice, 2003; Kummerer and Rice, 2002).  
4.2.5 The NS3 protein 
The NS3 protein is the second largest viral protein (70 kDa) and is a multifunctional 
membrane-associated protein with protease, helicase and RNA triphosphatase activities. 
The serine protease is required for polyprotein processing (Pastorino et al., 2010; Assenberg 
et al., 2009) while the helicase/NTPase activity is needed for unwinding the double stranded 
replicative form of RNA and the RNA triphosphatase activity is needed for capping nascent 
viral RNA (Bollati et al., 2009). Much of the available information about NS3 has been 
derived from crystallographic studies of the MVEV protein that is a member of the JEV 
serogroup. Recent structural data reveal that this single protein has two segregated domains 
connected by a linker domain (residues 169-181). The relative orientation of these domains 
differs between different flaviviruses and the helicase and protease activities are 
independent of each other (Assenberg et al., 2009). 
Residues 1 to 169 mediate the trypsin-like serine protease activity and contain the 
characteristic catalytic triad (Asp-His-Ser) as well as a highly specific substrate recognition 
sequence that is conserved in all flaviviruses (Chambers et al., 1990). The presence of an 
aberrant fold makes its structure different from the canonical trypsin structure and makes it 
dependent on a noncovalent association with a 47 amino acid hydrophilic stretch of NS2B 
for its proteolytic activity. NS3 cleaves at the C-terminal side of highly conserved dibasic 
residues located between NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4B/NS5.  
Residues 170 to 619 mediate the activities of RNA strand separation and (poly)nucleotide 
hydrolysis. The structure of this region has been solved for JEV (Yamashita et al., 2008) and 
other flaviviruses (Luo et al., 2008; Wu et al., 2005). These studies show that NS3 is a 
member of the DEAH/D family of helicase superfamily (SF2) containing the Walker A and 
B motifs that are responsible for NTP and Mg2+ binding. It’s abilities to separate nascent 
from template RNA strands and to unwind RNA secondary structure in the 3’ untranslated 
region is presumed to assist RNA replication. The RNA 5’ triphosphatase activity is thought 
to facilitate viral RNA capping by removing the terminal Ǆ-phosphate. In addition to its 
interaction with NS2B which is a cofactor required for its proteolytic activity, NS3 has also 
been shown to interact with NS5 as a result of which its helicase/NTPase activity is 
stimulated. The NS3 protein of JEV has also been shown to interact with Src resulting in NS3 
tyrosine phosphorylation although the significance of this phosphorylation is still unclear 
(Raung et al., 2007). Thus, its multifunctional activities have made NS3 an attractive target 
for antiviral strategies. 
4.2.6 The NS4A & NS4B protein 
Flaviviruses mediate late cytoplasmic membrane rearrangements that occur after the virus 
latency period in order to facilitate efficient RNA replication (Westaway et al., 1997). Such 
rearrangements that involve microtubules and microtubule-associated proteins may 
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facilitate efficient JEV replication by enabling intracellular trafficking of viral components. A 
certain threshold of viral RNA replication was found to be required for the formation of 
these structures indicating that cellular membrane biogenesis was closely linked to viral 
RNA replication and protein synthesis. Three types of membrane structures are induced 
called convoluted membranes (CM), paracrystalline arrays (PC) and vesicle packets. The 
CMs are derived from the RER while the vesicle packets are derived from the trans-golgi 
region of infected host cells. Antibody staining for virus and host-specific proteins reveals 
that each of these structures perform specific functions during viral replication. Although 
not shown for JEV, studies with KUNV and WNV suggest that flaviviral NS4A protein 
mediates these cytoplasmic membrane rearrangements. The cleavage of the NS4A-4B 
polyprotein intermediate by the NS3-2B protease serves as the signal for the induction of 
cellular membrane biogenesis and allows NS4A targeting to the golgi complex where viral 
replication occurs. The exact nature of NS4A cleavage fragments that are involved in these 
processes as well as the role of NS4A and NS4B in viral replication is still unclear 
(Roosendaal et al., 2006). Information about posttranslational modifications despite the 
presence of a conserved, potential N-linked glycosylation site in the C-terminal portion of 
NS4B is also not clear (Chambers et al., 1990). However, it has recently been demonstrated 
that the peptidyl-prolyl isomerase (PPIase) function of cyclophilin B (CypB) is essential for 
JEV replication and that CypB interacts with NS4A in JEV infected cells (Kambara et al., 
2011). Also, NS4A has been shown to function as an IFN antagonist (Lin et al., 2008a). 
4.2.7 The NS5 protein 
NS5 is the largest (105 kDa) and most highly conserved flaviviral protein that has been 
crystallized and characterized clearly. Like NS3, NS5 is also a multifunctional protein and 
contains two distinct enzymatic activities of S-adenosyl methyltransferase and RNA-
dependent RNA polymerase (RdRp) (Davidson, 2009; Kim et al., 2007) that are separated by 
an interdomain region. The former resides in the N-terminal domain and is probably 
involved in performing sequential N7 and 2’ O methylations after the terminal Ǆ phosphate 
is removed by NS3 during the capping process. The RdRp activity that resides in the C 
terminal domain of NS5 is majorly responsible for de novo initiation of viral RNA synthesis. 
NS5 can be phosphorylated by a serine/threonine kinase and this phosphorylated form has 
been shown to localize to the nucleus presumably via the nuclear localization signals that 
are found in its NS3-interacting interdomain region. In addition to its interaction with the C 
terminal domain of NS3 as mentioned above, NS5 may also be involved in interactions with 
several other nonstructural proteins that may be required for its association with other 
replicase components (Khromykh et al., 1996) and to facilitate virus replication, maturation 
and assembly. It has also been shown that NS5 has a phosphatase activity which reverses 
Stat-1 phosphorylation and inhibits IFN responses (Lin et al., 2006). 
5. Immune responses to JEV 
Both innate and adaptive immune responses are activated in response to JEV infection and 
have been shown to reduce serum viraemia and viral loads in infected tissues. These 
immunological responses – both humoral and cellular are the subject of active investigation. 
Humoral responses play a central role in protection against JEV. However, cell mediated 
immune responses contributing to this end are not fully understood. In fact, both clinical 
and experimental data clearly show that IgM and IgG humoral immune responses act in 
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conjunction with cellular immune responses to prevent virus dissemination and persistence 
as well as resolution of CNS infection. Ironically, the same protective immune responses can 
also become pathological and cause immune-mediated damage to the host. 
5.1 Humoral immune response to JEV 
The presence of IgM in the cerebrospinal fluid (CSF) of patients within 5-7 days appears to 
be a positive prognostic indicator in patients infected with JEV for the first time. Raised IgM 
levels are present seven days after infection with JEV in the sera and CSF of most 
symptomatic patients (Solomon et al., 2000). However, raised IgM levels are observed only 
in the serum but not in the CSF of asymptomatic patients. Maximal levels of serum IgM 
occur from about day 9 onwards after the onset of clinical disease. Isolation of virus has 
been possible only in patients who lack the primary IgM response and is usually associated 
with fatal outcome. Hence diagnostic tests are based on the capture of anti-JEV IgM from 
patient sera (Shrivastva et al., 2008; Ravi et al., 2006). This primary IgM response leads to 
class switching and production of IgG by 30 days after infection only in patients who 
survive. Neutralizing antibodies lead to inhibition of virus replication and virus spread in the 
initial stages while in encephalitic patients, antibody mediated inhibition of virus replication 
leads to the inhibition of the cytopathic effects of the virus and hence less tissue damage.  
Protection from JEV challenge has been shown to be mainly antibody dependant and virus 
neutralizing antibodies alone are sufficient for conferring protection. Passive immunization 
of neutralizing monoclonal antibodies raised against E protein protects mice from lethal 
challenge with JEV (Zhang et al., 1989; Kimura-Kuroda and Yasui, 1988). Sub-viral particles 
consisting of prM in addition to E proteins were highly effective in generating a protective 
immune response in mice against JEV (Konishi et al., 1992b; Mason et al., 1991). The critical 
role of antibodies in protection against JEV has also been shown using mice lacking 
immunoglobulins (Pan et al., 2001) as mentioned later in the chapter. It has been shown that 
humanized monoclonal antibodies derived from chimpanzees protect mice from lethal JEV 
challenge. These protective antibodies were against different domains of E protein and 
exhibited high neutralizing activities against a broad spectrum of JEV genotype strains 
(Goncalvez et al., 2008).  
Antibody responses have been observed against many nonstructural proteins but none 
except anti-NS1 antibodies were protective in nature. However, even these could provide 
only low protection from JEV infection. A recent study has shown that the E. coli expressed 
NS1 protein induces protective humoral immune response in mice during JEV infection (Lin 
et al., 2008b). The low level of protective immunity of NS1 was previously proposed to rely 
on the NS1-specific antibody-dependent complement-mediated cytolysis of the JEV-infected 
cells (Lin et al., 1998). However, anti NS1 antibodies can directly effect reduction in virus 
titres from infected cells (Krishna et al., 2009). Immunization of mice with recombinant 
vaccinia viruses that express various JEV gene products such as E, prM, M and NS1 have 
also been reported to confer protection against lethal JEV challenge in mice (Konishi et al., 
1992a; Mason et al., 1991; Yasuda et al., 1990). 
Enhanced neurovirulence of JEV has also been reported in mouse models by passive 
transfer of virus-specific antibodies. Such enhanced neurovirulence is thought to be 
mediated by antibody dependent enhancement (ADE) of virus infection due to the 
internalization of antibody-virus complexes into cells via FcǄ or complement receptors (Gould 
and Buckley, 1989). The role of non-neutralizing antibodies in increasing infection via antibody 
dependent enhancement (ADE) is still unclear although this has been thought to contribute to 
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the immunopathological activity of anti-flaviviral humoral responses. ADE has been observed 
with DNV (Kliks et al., 1989), YFV (Gould and Buckley, 1989) and other flaviviruses. 
It has also been shown that oral immunization of mice with live JEV generates a brisk and 
protective immune response. It was also observed that more robust IgG1 antibody response 
against JEV occurs following oral infections compared to intraperitoneal (i.p) or subcutaneous 
(s.c) infections in C57BL/6 and Swiss albino mice (Ramakrishna et al., 2003). However, oral 
immunization of mice with JEV envelope protein that was expressed in E. coli also led to the 
generation of low neutralizing titre antibodies that were not protective. This result was 
ascribed to the lack of glycosylation and lack of correct folding in the E. coli expressed protein. 
Despite the presence of comprehensive data that point out the important role of antibodies 
in protection, differences in the role of humoral responses in different flaviviruses are 
evident in studies that utilize mice lacking B cell function. In the case of WNV, mice lacking 
B cells are more susceptible to the disease while such mice show no change in disease 
severity in the case of dengue virus (Diamond et al., 2003).  
5.2 Cell mediated immune response to JEV 
The activation of T cell immunity during JEV infection is an area of intense scrutiny but its 
role is less clear. In early studies, thymus-deprived mice showed an impaired anti-JEV 
antibody response indicating the importance of T cell responses in generating B cell 
immunity to JEV infection (Mori et al., 1970). Similarly, the suppression of T cell function in 
spider monkeys that are normally resistant to JEV-induced disease resulted in their 
susceptibility (Nathanson and Cole, 1970). Life long cell mediated immunity could be 
conferred by passive transfer of immune spleen T cells in mice (Jia and Huang, 1983). The 
role of T cells in JEV infection was indicated in infection studies involving T cell deficient 
(nu/nu) nude mice, wherein it was observed that T cells were required for recovery (Lad et 
al., 1993) and protection after i.p. challenge with JEV (Miura et al., 1990). Adoptive transfer 
studies had shown that adult but not newborn mice were protected from JEV infection 
when JEV primed purified T cells were given intracerebral (i.c.) along with 10 x LD50 JEV. It 
was also shown that CD4+ and CD8+ T cells were necessary in protection from JEV and 
depletion of either population abrogated the protective ability of transferred effectors 
(Murali-Krishna et al., 1996). However, other reports have not supported a role for T cells in 
protection from JEV infection (Pan et al., 2001). In their study, neither enriched JEV primed 
T cells nor B cells were able to protect mice from JEV infection. Further, in their JEV 
challenge experiments in immunoglobulin (Ig), CD4+ or CD8+ T knockout mice immunized 
with envelope DNA vaccine, it was observed that protection was abrogated only in Ig and 
CD4+ knockout mice but not in CD8+ knockout mice suggesting that only CD4+ but not CD8+ T 
cells were required for protection. Nonetheless, CD8+ T cell activation may contribute to 
disease pathogenesis in the case of other flaviviruses. It has been shown that mice lacking 
perforin and Fas/FasL expression were protected from MVEV-induced disease (Licon Luna 
et al., 2002). Similarly a immunopathological role for CD8+ T cells has been reported for 
dengue virus (An et al., 2004). 
JEV specific T cell responses were observed in peripheral blood mononuclear cells (PBMCs) 
collected from vaccinees who had received a purified formalin inactivated JEV vaccine as 
well as JEV patients (Konishi et al., 1995). Both CD4+ and CD8+ T cell subsets directed 
against structural proteins were observed in PBMCs isolated from vaccinees that are 
directed against structural proteins. In contrast, PBMCs from JEV patients showed CD4+ and 
CD8+ responses to nonstructural or C proteins.  
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Nonstructural proteins play a major role in the initiation of T cell responses and among the 
non-structural proteins, NS3 is the major target of JEV-specific cell mediated immune 
responses, whereas NS5 is the weakest. In another study, cytolytic CD4+ T cell clones have 
been generated from PBMCs of individuals immunized with inactivated JEV vaccine 
(Aihara et al., 1998). These CD4+ CTLs recognized the envelope protein and were flavivirus 
cross reactive in nature. The significance of such CD4+ T cells in an in vivo context is not 
clear. NS3 protein (region aa193-324) is a dominant source of epitopes for both CD4+ and 
CD8+ T cells in PBMCs isolated from children belonging to a JE endemic region of India. 
NS3 stimulated IFN-Ǆ production by both the CD4+ and CD8+ T cells indicates that a Th1 
immune response to the NS3 protein may be a critical determinant of immune control 
during JEV infection (Kumar et al., 2004a; Kumar et al., 2004b). Recombinant JEV domain III 
has also been shown to elicit a Th1 type of response in Balb/c mice (Verma et al., 2009). 
JEV infection using the mouse model has been reported to result in differential secretion of 
cytokines in the brain, spleen and sera that depended on the route of inoculation. This 
differential secretion could influence the overall balance between Th1 and Th2 
predominance after infection and thus determine its outcome. The expression of IL-4 and IL-
10 increased immediately after intracerebral (i.c.) challenge with virus and decreased later as 
virus load increased with concomitant increases in the expression of TNFǂ and IFN-Ǆ. The 
levels of IL-4 and TNFǂ but not IL-10 and IFN-Ǆ increased in the serum of these challenged 
animals (Saxena et al., 2008a). However, intraperitoneal challenge resulted in an increase in 
the expression of all these cytokines in the spleen (Saxena et al., 2008b). Thus, while TNFǂ 
and IFN-Ǆ could be involved in rapid virus clearance from the periphery, they could 
exacerbate inflammation within the CNS. 
Recent reports suggest that different flaviviruses are able to infect dendritic cells (DCs) both 
in vitro and in vivo and alter their phenotype and function (Cao et al., 2011). JEV is able to 
infect macrophages as well as dendritic cells derived from the bone marrow and spleen but 
it appears to have dual action on these two different antigen presenting cells of the immune 
system. Macrophages and DCs are antigen presenting cells that produce several cytokines 
such as TNFǂ and IL-6 upon virus infection or activation (Zhang et al., 2001). DC maturation 
is associated with increased antigen presentation, increased synthesis and secretion of 
proinflammatory cytokines such as TNFǂ, IL-12 and IL-6, upregulation of costimulatory 
molecules such as CD80, CD86 and CD40 and alteration of chemokine receptors (Kawai and 
Akira, 2006). They are also the principal cells that express toll-like receptor (TLR) molecules 
for pathogen recognition and therefore, important for innate immune responses. JEV 
infection of macrophages resulted in increased synthesis of cytokines and costimulatory 
markers but JEV infection of DCs in vitro led to suppressed activation, enhanced CCL2 
(MCP-1) release and more prominently secretion of IL-10, a cytokine that suppresses T cell 
response (Pestka et al., 2004). All these mediators namely TNFǂ, IL-10, CCL2 and type I 
IFNs are crucial modulators of viral infections and have the ability to alter the polarization 
of Th1 and Th2 cells. Endogenous IL-10 has also been shown to decrease during JEV 
infection (Swarup et al., 2007a) using immuno-histochemical approaches. However, the 
observation that infected DCs activated Foxp3+ regulatory T (Treg) cells suggests that JEV 
may have the ability to suppress ongoing immune responses although this ability may not 
be sufficient to suppress the virus-triggered inflammatory response. Taken together with the 
observation that the highly efficient vaccine strain SA14-14-2 of JEV stimulated DC function 
and suppressed Foxp3+ Treg cells suggests an important role for dendritic cells in the JEV 
mediated disease process (Li et al., 2011). JEV infection has also been found to result in the 
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depletion of splenic CD8ǂ+CD11c+ DCs as well as suppression of MHC-I mediated antigen 
presentation leading to suppression of CD8+ T cells (Aleyas et al., 2010).  
DCs play a critical role in antigen presentation and alterations in DC function will lead to 
altered adaptive immune responses. However, DCs are also capable of initiating innate 
immune responses against viruses through TLRs that are expressed on the cell surface or 
intracellularly. TLRs use the pan adaptor MyD88 molecule to transduce downstream TLR 
signaling events. The cytokine profile induced in JEV infected DCs from wild type mice was 
considerably reduced in DCs that were obtained from TLR2 and TLR3 deficient mice. JEV-
induced functional impairment of DCs finally led to altered CD4+ and CD8+ T cell function. 
It is hence significant that this was mediated through MyD88 dependent and independent 
signalling pathways implicating the involvement of TLRs in JEV pathogenesis (Aleyas et al., 
2009). TLR3 plays a role in WNV entry into the CNS and has been shown to play an 
important immunopathological role in the WNV induced CNS disease. TLR3 deficient mice 
show an impaired microglial TNFǂ response and hence decreased primary neuronal 
damage and absence of encephalitis (Wang et al., 2004). All these observations suggest that 
JEV can modulate both adaptive and innate immunity.  
6. Pathogenesis 
Altered cytokine secretion profiles and the balance between proinflammatory and anti-
inflammatory cytokines determine the outcome of disease processes. Immunoprotective 
responses to JEV infection lead to the secretion of proinflammatory cytokines in the initial 
phases but overproduction of these cytokines shift the balance and cause neuronal injury. 
JEV infection in humans is associated with elevated levels of proinflammatory mediators 
such as IFNǂ, TNFǂ, MIF, IL-8, IL-6, (CCL5) RANTES, Cox-2, IL-1ǃ and (CCL2) MCP-1 
(Ghoshal et al., 2007; Burke and Morill, 1987) in the CSF and/or serum. Increasing levels of 
such cytokines in the serum and CSF of JEV patients have been correlated with higher 
mortality rates (Ravi et al., 1997).  
Activation of CNS cells such as microglia and astrocytes is a major histological feature of 
JEV infection both in animals and humans infected with JEV, MVE and WNV. JEV is a 
neurotropic virus and infects relatively immature neurons (Kimura-Kuroda et al., 1993), 
astrocytes and microglial cells which might serve as a reservoir for the virus (Thongtan et 
al., 2010). Several studies report the interaction of JEV with microglia and astrocytes leading 
to production of chemokines, inflammatory mediators and neuronal degeneration. The 
chemokines, CCL5 and CCL2 that are produced from JEV infected cells (Das et al., 2009a; 
Chen et al., 2004) result in the extravasation of activated T cells and macrophages into the 
brain and leads to the stimulation of microglial cells within the CNS. IL-6, MCP-1 and 
RANTES promote leukocyte infiltration into the brain while IP10 production by infected 
astrocytes leads to infiltration of NK cells and monocytes (Bhowmick et al., 2007).  
Neuronal degeneration as a consequence of JEV infection may be brought about directly or 
indirectly. Direct effects of JEV within neurons are due to virus replication leading to 
cytopathicity and cell death while indirect effects are due to the action of inflammatory 
mediators that are produced as a result of virus infection (Ghosh and Basu, 2009). Cytotoxic 
effects can be the result of oxidative stress caused by the overproduction of reactive oxygen 
species (ROS), free radical derivatives of molecular oxygen and hydrogen peroxide. JEV has 
been shown to activate the ROS mediated pathway (Lin et al., 2004b) and JEV infection of 
primary neurons/glia, mixed glia, microglia and astrocytes results in the stimulation of 
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RANTES production (Chen et al., 2004). TNFǂ and IL-1 released during the inflammatory 
processes occurring in the JEV infected CNS play an important role in the induction of 
RANTES gene expression. These responses along with other proinflammatory cytokines 
increase upon JEV infection of cells within the CNS and lead to uncontrolled microglial 
activation and neuronal cell death. Although activated astroglial cells have the ability to 
neutralize the toxic effects of free radicals, they may be unable to deal with the uncontrolled 
inflammatory effects of JEV infection (Ghosh and Basu, 2009). In addition to the triggering of 
an inflammatory cascade, JEV has been shown to inhibit the proliferation of neural progenitor 
stem cells and thus block the replenishment of damaged neural cells which could be one of the 
reasons for the sequelae that are observed in surviving JEV patients. Nitric oxide (NO) is also 
another antiviral factor secreted from the infiltrating leukocytes and blocks virus replication 
(Lin et al., 1997) but the high levels of NO produced cause oxidative bystander damage 
leading to further neuronal damage. NO plays an important role in other flaviviral infections 
as well and has been reviewed elsewhere (King et al., 2007). 
Programmed cell death (PCD) or apoptosis is a prominent consequence of flaviviral 
replication within infected cells and the ensuing release of inflammatory mediators such as 
TNFǂ (Ghosh and Basu, 2009). JEV infection triggers perturbation of ER homeostasis and 
the unfolded protein response, thus accelerating ER stress-induced apoptosis (Liao et al., 
1997). Apoptosis can also be mediated by the virus induced release of ROS which is an 
antiviral defense response. JEV infection has been shown to cause apoptosis of 
neuroblastoma cells and activates caspase 8 and 9 in a FADD-independent and 
mitochondrion-dependent manner (Tsao et al., 2008). JEV non structural protein NS3 along 
with NS2B expression enhances apoptosis via caspase-3 activation as well as decreased 
mitochondrial membrane potential in human medulloblastoma cells (Yang et al., 2009). 
Many of the observations made above have been supported by the results obtained recently 
from genomic expression profiling. Whole genomic expression profiling by cDNA 
microarray of JEV infected mouse brain cerebral cortex (Gupta and Rao, 2011) revealed the 
activation of several genes participating in immune response, inflammatory response, cell 
adhesion, defense response, proteolysis, endocytosis and chemokine signaling. Several other 
genes involved with the cell cycle, endocytosis, leukotriene metabolism, signal transduction, 
transcription, cell adhesion and apoptosis were downregulated during the course of disease. 
Significantly, genes encoding caspases 1 and 5 characteristic of the inflammasome complex 
were upregulated supporting the occurrence of inflammation during JEV infection. 
Although the exact manner in which the plethora of upregulated genes play a role in JEV 
mediated disease is still to be worked out, it is significant that many lectin receptors, TLR 2 
and 3, OAS family, guanylate nucleotide binding proteins and TRIM family of proteins are 
among those that are altered. In general, these results corroborate the expression profiles 
that have been reported for WNV (Koh and Ng, 2005; Venter et al., 2005).  
7. Interferons, MHC and NF-κB mediated regulation 
IFNs play a major role in viral infections and the importance of type-I and type-II IFN in 
controlling viral infection was clearly demonstrated in mice which are unresponsive to 
either IFN-ǂ/ǃ or IFN-Ǆ (Muller et al., 1994). Type-I IFN mediated immune response is the 
main innate immune mechanism of the host against viral infection. IFNs are one of the best 
characterized components of the immune system. They act in paracrine fashion to induce 
gene expression through the engagement of cell surface IFN receptors and by activating the 
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Jak-Stat signaling pathway. The coordinated activities of multiple cellular transcription 
factors such as IRFs, NF-κB, and c-Jun/ATF-2 are responsible for the induction of type-1 
IFNs during viral infection (Doly et al., 1998; Wathelet et al., 1998). During JEV infection, 
both NF-κB and interferon regulatory factor-3 (IRF3) mediated signaling events are involved 
in the induction of IFN-β (Chang et al., 2006). WNV infection has been shown to induce IFN-
ǃ and several IFN-stimulated genes (ISG) late in the infection of cultured cells due to the 
delayed activation of IRF-3 (Fredericksen et al., 2004). High levels of IFN-ǂ have been 
detected in patients with dengue fever or dengue hemorrhagic fever (Kurane et al., 1993). 
IFN-ǂ activity was also detected in the plasma and cerebrospinal fluid specimens from 
patients infected with JEV (Winter et al., 2004; Burke and Morill, 1987). Type-I IFNs are 
produced by most cell types soon after viral infection whereas, IFN-Ǆ is produced by a 
restricted set of cells of the immune system such as NK cells, CD4+ T helper 1 (Th1) cells and 
CTLs. Although IFN-Ǆ may play a protective role, it has been shown that lethality was less 
severe in WNV infected IFN-Ǆ knockout mice suggesting that IFN-Ǆ may be a contributory 
factor in the establishment of immunopathology (King et al., 2007). 
Pretreatment of cell cultures with IFN-α and IFN-β inhibits the replication of flaviviruses 
including JEV, YFV and WNV (Ajariyakhajorn et al., 2005; Samuel and Diamond, 2005; 
Scherbik et al., 2007) However, the use of IFN-α in clinical trials for the treatment of JEV 
infection has not been successful (Solomon et al., 2003). This may be because many 
flaviviruses such as JEV, WNV and KUNV have developed different strategies to overcome 
the antiviral activities of type-I IFNs (Liu et al., 2005; Munoz-Jordan et al., 2005; Guo et al., 
2005; Lin et al., 2004a; Munoz-Jordan et al., 2003). NS2A of WNV prevents the translocation 
of Stat1 and Stat2 into the nucleus by preventing their phosphorylation (Liu et al., 2006a). 
JEV is known to escape from the action of IFNs by preventing both Tyk2 tyrosine 
phosphorylation as well as Stat activation, thereby blocking the IFN stimulated Jak-Stat 
signaling (Lin et al., 2004a). This inhibition of Tyk2 tyrosine phosphorylation and Stat 
activation is mediated by the nonstructural protein NS5 of JEV (Lin et al., 2006). It has recently 
been shown that JEV encoded NS4A is able to block the phosphorylation of Stat1 and Stat2 but 
not Tyk2 activation in response to IFN-ǂ/ǃ (Lin et al., 2008a). In addition to IFNs, ISGs 49, 54 
and 56 as well as the double stranded RNA activated protein kinase (PKR) and 2’,5’-
oligoadenylate synthetase may play important roles in flavivirus infections (King et al., 2007). 
NF-κB induced transcriptional activation plays an important role in the production of type-I 
IFNs during viral infection and the consequent initiation of antiviral immune responses. 
Many viruses have evolved different strategies either to disrupt or activate NF-κB signaling 
and modulate host immune response with the help of viral proteins. The NF-κB activation 
by viruses such as HIV-1, HTLV-1, HHV8, EBV and Influenza virus serves different 
functions such as to promote viral replication, to prevent virus-induced apoptosis as well as 
to modulate cellular apoptosis and growth (Hiscott et al., 2006; Hiscott et al., 2001). It has 
been shown that both JEV and WNV infections induce NF-κB activation (Kesson and King, 
2001; Liao et al., 2001). 
There are 2 different pathways of NF-κB activation, the classical or canonical pathway and 
the alternate or noncanonical pathway. The NF-κB factor is a dimer composed of different 
Rel proteins and is retained in the cytoplasm of a resting cell by three inhibitor proteins, 
IκBǂ, IκBǃ and IκBǆ. In the canonical pathway, stimulus-responsive phosphorylation of the 
IκBs by IκB kinase (IKK) complex leads to their degradation to allow for nuclear 
translocation of the NF-κB dimers. The IKK complex is composed of two catalytic subunits, 
IKK1 (IKKǂ), and IKK2 (IKKǃ) and the regulatory subunit IKK3 (NEMO). IKK1 kinase is 
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dispensable for the canonical pathway of NF-κB activation (Scheidereit, 2006). However, the 
noncanonical pathway critically depends on IKK1 activity for NF-κB signaling. Hence 
mutant mouse embryonic fibroblasts lacking in any one of these kinases or the Rel 
counterparts have been used to dissect the roles of the canonical and noncanonical 
pathways (Basak and Hoffmann, 2008). Both the classical and the alternate NF-κB signaling 
pathways play important but distinct roles in the functioning of the immune system. The 
classical pathway is largely responsible for the regulation of inflammation as well as the 
control of proliferation and apoptosis of lymphoid cells during the immune response. In 
contrast, the alternate pathway is associated with the development of lymphoid organs that 
ensure the mounting of an effective immune response. JEV infection also activates NF-κB in 
glial cells and primary mouse brain astrocytes (Abraham et al., 2008; Liao et al., 2001). Using 
IKK1-/-, IKK2-/-, IKK3-/- and IKK1-/-IKK2-/- double mutant as well as RelA-/-cRel-/-p50-/-- 
triple mutant mouse embryonic fibroblasts infected with JEV, it has been shown that JEV 
activates the classical pathway of NF-κB activation in a IKK2- and IKK3- but not IKK1-
dependent manner that involved RelA and p50 complexes. NF-κB dependent and 
independent mechanisms also critically determined type I IFN induction in JEV infected 
MEFs (Abraham et al., 2010).  
In addition to its involvement in immune responses, apoptosis and the cell cycle (Bonizzi 
and Karin, 2004), NF-κB has been shown to play a major role in flavivirus-mediated 
induction of MHC-I (Cheng et al., 2004). Both NF-κB dependent and independent 
mechanisms regulate WNV-induced MHC-I expression on infected cells. MHC molecules 
play an important role in host responses to viral infection and the consequences of virus 
infection on the expression of MHC molecules are varied. Many viruses such as HIV, 
MCMV, HCMV, AdV and EBV are known to decrease the expression of MHC molecules 
upon infection (Lilley and Ploegh, 2005). On the other hand, WNV induces the cell surface 
expression of both MHC-I and MHC-II molecules (Kesson et al., 2002) and the induced 
MHC-II was functionally intact in mouse brain astrocytes since it was associated with better 
recognition by a class II MHC reactive T cell line (Liu et al., 1989). In contrast to WNV, JEV 
infection of primary mouse brain astrocytes induces MHC-I but is unable to induce MHC-II. 
JEV-induced MHC-I expression was also associated with induced transcription of molecules 
involved in antigen processing and presentation such as Tap1, Tap2, Tapasin, Lmp2, Lmp7 and 
Lmp10 (Abraham and Manjunath, 2006). The absence of MHC-II induction during JEV 
infection could be important because it may lead to the initiation of an immune response 
which is different from other flaviviral infections that induce the expression of MHC-II 
molecules. Again, in contrast to WNV, the use of knockout MEFs showed that JEV-mediated 
induction of classical MHC-I molecules remained unaffected in NF-κB defective cells but was 
completely dependent on type I IFNs (Abraham et al., 2010). 
In contrast to classical MHC molecules, the nonclassical MHC molecules do not belong to a 
single group of structurally and functionally homologous proteins and normally have lower 
cell surface expression. They play an important role in bridging adaptive and innate 
immune responses. Nonclassical MHC-I family members include gene products from HLA-
E, F, G and H in humans and H2-Q, H2-T and H2-M regions in mice (Shawar et al., 1994). 
JEV infection of primary mouse brain astrocytes induced the expression of nonclassical 
MHC-I or class Ib molecules in addition to the induction of classical MHC-I molecules 
(Abraham and Manjunath, 2006). Given the distinct regulations of the classical and 
nonclassical MHC-I molecules, it was of interest to evaluate the role of the NF-κB pathway 
in nonclassical MHC-I gene expression. 
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We analyzed the role of NF-κB mediated signaling in the induction of nonclassical MHC-I 
molecules during JEV infection. WT, IKK1-/-, IKK2-/- and IKK3-/- MEFs were harvested at 
different time intervals p.i. and expression of nonclassical MHC-I molecules was analyzed 
by semi quantitative RT-PCR analysis. As shown in Figure 2A, JEV infection induced the 
transcription of Qa-1, T10 and Qb1 in IKK1-/-, IKK2-/- and IKK3-/- MEFs. To further validate 
this observation that the induction of nonclassical MHC-I molecules during JEV infection 
occurs independent of NF-κB activation, IKK1-/-IKK2-/- double mutant MEFs were 
harvested at different time intervals p.i. and expression of nonclassical MHC-I molecules 
was analyzed by semiquantitative RT-PCR. As shown in Figure 2B, JEV infection induced 
the transcription of Qa-1 and Qb1 in IKK1-/-IKK2-/- MEFs confirming our results that JEV-
induced expression of Qa-1 and Qb1 occurs independent of NF-κB activation. The role of 
type-I IFNs in the induction of nonclassical MHC-I molecules during JEV infection was then 
determined. IFNAR-/- and IFNGR-/- MEFs were harvested at different time intervals p.i. and 
the expression of Qa-1, Qb1 and T10 was analyzed by RT-PCR analysis as above. As shown 
in Figure 2B, our RT-PCR results demonstrated that JEV-induced expression of nonclassical 
MHC-I molecules, Qa-1 and Qb1 was completely abrogated in IFNAR-/- MEFs but not in 
IFNGR-/- MEFs. In contrast, the expression of T10 was not altered in IFNAR-/- and IFNGR-/- 
MEFs. Thus, our results clearly show that JEV-induced expression of Qb1 and Qa-1 was 
dependent on type-I IFN mediated signaling. In contrast, the induction of T-10 was 
independent of type-I IFN mediated signaling. 
The functional role of the induced nonclassical molecule T10 in the activation of Ǆǅ T cells 
was further analyzed. JEV infected cells were added to a cloned Ǆǅ T cell clone called G8 
that responds by secretion of IL-2 upon specific recognition of the T10 molecule on the 
surface of cells. The G8 clone was kindly provided by Dr Chien, Stanford university school 
of medicine, USA. As shown in Fig 2C, exposure of G8 to JEV infected H-6 cells resulted in 
IL-2 secretion suggesting that the induced T10 on H6 could be functional. However, the 
relevance of this observation in the larger in vivo context is still unclear.  
The involvement of Ǆǅ T cells has been shown in the case of WNV but no information is 
available with JEV. Mice deficient in TCRǅ (TCRǅ-/-) were found to be more susceptible to 
WNV infection and exhibited higher viral titres in blood and lymph organs (Wang et al., 
2003). A higher IFN-Ǆ production and enhanced perforin expression in splenic T cells  
in WT mice as compared to TCRǅ-/- mice was proposed to be responsible for higher 
survival of WT mice in WNV infection. In a recent report, it has been shown that WNV is 
capable of infecting Ǆǅ T-cells which leads to maturation of dendritic cells by production 
of IFN-Ǆ, TNF-ǂ and IL-6, thus facilitating adaptive immune responses as well (Fang et 
al., 2010).  
The avidity of T cell-target interactions and the threshold for T cell activation is the result of 
both specific (MHC-I associated) as well as nonspecific interactions due to adhesion 
molecules such as ICAM-1 (Lebedeva et al., 2005). Hence, virus-induced alterations in 
ICAM-1 and/or VCAM-1 expression can lead to alterations not only in T cell activation but 
also in the leukocyte subsets attaching to the infected cells and consequently altering host 
cell-virus interactions. In addition to inhibition of IFN signaling, flaviviruses have been 
shown to modulate the expression of MHC and adhesion molecules such as VCAM and 
ICAM on the cell surface. Using endothelial cells, it has also been shown that flaviviruses 
such as WNV increases the cell surface expression of adhesion molecules such as ICAM-1, 
VCAM-1 as well as E-selectin. These changes were mediated by WNV in a NF-κB dependent 
but IFN and TNF independent manner (Shen et al., 1997).  
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We have reported that the cell surface expression of adhesion molecules ICAM-1 and 
VCAM-1 was significantly induced on primary astrocyte cultures but not hepatoma cells, 
L929 and 3T3 fibroblasts. Hence we observed that the JEV induced the cell surface 
expression of adhesion molecules does not occur uniformly on all cell types (Abraham et al., 
2008). Since NF-κB transcriptionally controls the expression of ICAM-1 and VCAM-1, we 
further analyzed the role of NF-κB in the induction of adhesion molecules by JEV. Only 
VCAM-1 but not ICAM-1 was induced by JEV on mouse embryonic fibroblasts (MEFs) and 
knockout MEFs are the cell types that are generally utilized for analyzing the role of this 
transcriptional factor in gene induction studies. Hence WT (wild type), IKK1-/-, IKK2-/- and 
IKK3-/- MEFs were harvested at different time intervals p.i. and expression of VCAM-1 was 
analyzed by flow cytometry. As shown in Figure 3, JEV infection induced the cell surface 
expression of VCAM-1 in IKK1-/-MEFs but not in IKK2-/- and IKK3-/- MEFs. The basal level 
of expression of VCAM-1 was high in IKK2-/- and IKK3-/- MEFs. We also analyzed the status 
of VCAM-1 in IKK1-/-IKK2-/- double knockout and RelA-/-cRel-/-p50-/-triple knockout MEFs 
upon JEV infection by flow cytometry. As shown in Figure 3, JEV-induced expression of 
VCAM-1 was completely abrogated in both mutants. The basal level of expression of 
VCAM-1 was high in IKK1-/-IKK2-/- MEFs whereas, it was low in RelA-/-cRel-/-p50-/- MEFs. 
This lack of induction of VCAM-1 in RelA-/-cRel-/-p50-/- MEFs indicates that the canonical 
pathway of NF-κB mediated signaling events are involved in the induction of VCAM-1 
during JEV infection.  
To determine whether JEV infection induces the expression of VCAM-1 molecules on MEFs 
deficient in IFN signaling, WT, IFNAR-/- and IFNGR-/- MEFs were harvested at different 
time intervals p.i. and the expression of VCAM-1 was analyzed by flow cytometry. As 
shown in the Figure 3, there was no induction of VCAM-1 on both IFNAR-/- and IFNGR-/- 
MEFs during JEV infection. All these results indicated that both NF-κB and type-I IFNs play 
a major role in the induction of VCAM-1 during JEV infection.  
It has been reported that the induction of VCAM-1 molecules in response to TNF-α 
treatment is mediated by the coordinated activity of NF-κB and IRF-1 (Neish et al., 1995). It 
has also been reported that the Concanavalin A (Con A) induced expression of VCAM-1 is 
reduced in IRF-1-/- hepatic cells as compared to that of WT cells (Jaruga et al., 2004). These 
results point to the importance of IRF-1 in the induction of VCAM-1 molecules. However, to 
our surprise there was no increase of VCAM-1 on JEV infected IFNAR-/- MEFs but it has 
also been reported that IL-6 mediated induction of IRF-1 was reduced in IFNAR-/- MEFs as 
compared to that of WT MEFs (Mitani et al., 2001). Hence, we believe that the defective 
activity of IRF-1 in IFNAR-/- MEFs may be responsible for the lack of induction of VCAM-1 
on IFNAR-/- MEFs upon JEV infection. This brings forth the possibility that even during JEV 
infection, the coordinated activity of both NF-κB and IRF-1 might be responsible for the 
induction of VCAM-1. At the same time there is one report which shows that IRF-1 is not 
activated upon JEV infection of human A549 cells (Chang et al., 2006) but the effects of JEV 
infection could be different on human cells. The mechanism of induction of ICAM-1 during 
JEV infection could not be characterized using knockout MEFs because ICAM-1 was induced 
only in astrocytes but not in MEFs. 
8. Vaccines and viral inhibitors 
Given the importance of flavivirus mediated encephalitis worldwide, it is not surprising that 
considerable efforts are underway to develop several antiviral strategies against these 
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viruses. These efforts include the development of antiviral drugs that inhibit not only the 
virus and its interactions with the host but also the development of vaccines that are aimed 
at strengthening antiviral immune responses as well as mosquito vector control measures to 
stop the spread of virus.The current vaccines that are under study are the inactivated mouse 
brain derived vaccine, the inactivated cell culture vaccines, the live attenuated vaccine, and 
the chimeric yellow fever/JE virus vaccine.  
The BIKEN (JE-VAX) vaccine is derived from formalin inactivated JEV infected mouse brain 
and a crude inactivated version was tested in Japan as early as 1930s. The currently available 
version was in use from 1966. Mouse brain derived inactivated JE vaccines are based on 
genotype-III strains Nakayama or Beijing-1. It is prepared by clarification of Nakayama or 
Beijing JEV infected mouse brain suspensions by low speed centrifugation, followed by 
formalin inactivation, ultrafiltration, ammonium sulphate precipitation, ultracentrifugation 
through a 40% sucrose density gradient and dialysis (Takaku et al., 1968; Oya, 1988). This 
vaccine has been found to induce both JE specific and flavivirus cross reactive HLA 
restricted CD4+ cytotoxic T cells directed against the envelope protein of the virus (Aihara et 
al., 1998). Vaccinated individuals exposed to infection with JEV have both memory B- and T-
cell and CTL responses to the envelope protein (Aihara et al., 1998; Konishi et al., 1995). 
Adverse reactions have also been observed in field trials with this vaccine. These include 
injection site reactions (erthema, swelling, tenderness) in approximately 20% volunteers and 
systemic side effects (fever, headache, malaise, rashes, chills, dizziness, myaglia, nausea, 
vomiting and abdominal pain) in 5-10% of volunteers (Andersen and Ronne, 1991; Ruff et al., 
1991; Poland et al., 1990; Hoke et al., 1988). This vaccine finds limited use in developing 
countries because of its high cost and has been discontinued from 2005 (Tauber et al., 2007). 
Effective formalin Inactivated cell culture derived vaccine was first produced and used in 
China since 1960s. This was prepared from JEV infected primary hamster kidney (PHK) cells 
(Tsai et al., 1999). The inactivated Beijing-3 virus produced from PHK cells is the P-3 
vaccine. Concerns about the presence of animal proteins in this vaccine led to development 
of cell culture vaccine from Vero cells infected with SA14-14-2 strain of JEV that has been 
adapted to PDK-8 (primary dog kidney cells). Its protective efficacy was tested in mice and 
phase I clinical trials (Srivastava et al., 2001). Similarly, another vaccine was derived from 
Vero cells infected with the Beijing strain of JEV. Phase I clinical trial of this Vero cell culture 
derived vaccine in 269 adult males identified a low rate of mild adverse events and greater 
or equivalent seroconversion rates compared to mouse brain derived vaccine (Kuzuhara et 
al., 2003; Sugawara et al., 2002). A vero cell-derived inactivated JE vaccine containing the 
purified, inactivated JEV strain SA14-14-2 with aluminum hydroxide as adjuvant has passed 
the Phase III randomized controlled trial (Tauber et al., 2007). A new inactivated vaccine 
licensed in US, Europe and Australia is also prepared from SA14-14-2 grown in Vero cells 
and is called IC-51 (IXIARO). 
Another important vaccine is the live attenuated SA14-14-2 vaccine, which is derived via 
extensive passage series in primary hamster kidney cells, followed by UV irradiation, 
plaque purification and passage in hamsters and suckling mice (Ni et al., 1994; Aihara et al., 
1991). SA14-14-2 was licensed in china in 1988 and provides 80-96% protection after a single 
dose and further studies in China have shown 97.5% efficacy after 2 doses 1 year apart 
(Tandan et al., 2007; Hennessy et al., 1996; Xin et al., 1988). Seroconversion of 99-100% and 
neutralizing antibody titres of 1:50 to 1:150 has been observed in field trials with this vaccine 
in China and South Korea (Tsai, 2000; Sohn et al., 1999; Tsai et al., 1999). Very few side 
effects were observed. It is now being used in Indian, Nepal and Sri Lanka.  
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Fig. 2. JEV infection and expression of nonclassical MHC-I molecules in wild type (WT) and 
mutant MEFs. Panel A represents the semi quantitative RT-PCR analysis carried out for 35 
cycles with uninfected and JEV infected WT, IKK1-/-, IKK2-/- and IKK3-/- MEFs. Panel B 
represents the semi quantitative RT-PCR analysis carried out for 35 cycles with uninfected 
and JEV infected WT, IFNAR-/-, IFNGR-/- and IKK1-/-IKK2-/- double mutant MEFs. Lane 1 
represents the result obtained from cells that were mock infected for 36 hr while lanes 2-4 
represent results obtained from cells infected for 12, 24 and 36 hr. Protocols, procedures and 
gene specific primers used are published elsewhere (Abraham et al., 2010). Panel C 
represents IL-2 secretion from G8, Ǆǅ T cell clone upon activation with JEV infected H6 
hepatoma cells. G8 cells were cultured for 24 hr alone (G8 only) or with H6 cells (Cont 
H6+G8), JEV infected H6 (JEV H6+G8) and H6 infected with UV inactivated JEV (UV JEV 
H6+G8). Uninfected H6 (Con H6) and infected H6 cultures were also cultured separately 
and the cell culture supernatants collected after 24 hr of stimulation were evaluated for IL-2 
secretion by ELISA (BD biosciences). Values in parenthesis represent the ratios of G8:H6 
cells used when 103 H6 cells were used for all cultures. Data from one of two different 
experiments are represented as fold stimulation relative to the IL-2 secretion from G8 
cultured alone for 24 hr. The G8 clone was obtained as a kind gift from Dr. YH Chien, 
Stanford University School of Medicine, California, USA (Crowley et al., 1997) 
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Fig. 3. JEV infection and expression of VCAM-1 on Wild type and knockout mouse embryo 
fibroblasts (MEFs) defective in NF-κB and interferon signaling. Wild type and knockout 
MEFs were infected with JEV for 24 and 36 hr and the cell surface expression of VCAM-1 
was analyzed by flow cytometry. Panel A: As indicated, the upper panel (CONTROL) 
represents uninfected cells while the lower panel (JEV) represents infected WT, IKK1-/-, 
IKK2-/- and IKK3-/- cells. Panel B: As indicated, the upper panel (CONTROL) represents 
uninfected cells while the lower panel (JEV) represents infected IKK1-/-IKK2-/- double 
mutant, RelA-/-cRel-/-p50-/- triple mutant, IFNAR-/- and IFNGR-/- cells. Unmarked 
histograms represent staining with FITC conjugated secondary antibody alone in both 
panels while arrow-marked histograms in the upper panel indicate staining with unlabeled 
primary antibody (clone 429; anti CD 106) followed by FITC conjugated secondary antibody. 
They represent basal VCAM-1 expression in uninfected cells. In the lower panel, the arrows 
represent 24 and 36 hr post infection. Protocols, procedures and nomenclature followed are 
published elsewhere (Abraham et al., 2010) 
A chimeric yellow fever/JE virus vaccine was constructed by Chambers et al. (1999) by 
substitution of prM and E genes from the highly attenuated YFV strain (strain YF17D) with 
that of JEV. Studies in mice and monkey models have shown that this chimeric vaccine was 
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highly immunogenic and protects the animals against lethal JEV i.c. challenge (Monath et 
al., 2000; Guirakhoo et al., 1999; Monath et al., 1999). Phase I and II clinical trials of the 
vaccine have been carried out and it was found to be well tolerated and induced 
neutralizing antibodies in 100% of naïve and yellow fever virus immune participants. In 
both trials it was found that a single dose of the chimeric vaccine was sufficient to elicit high 
titre of neutralizing antibodies (Monath et al., 2003; Monath et al., 2002). Although this 
vaccine was developed using genotype III virus, it stimulates protective antibodies against 
other genotypes as well (Beasley et al., 2004). 
In addition to the development of the vaccines mentioned above, numerous studies have 
utilized the importance of protective epitopes in the E and NS1 protein as the basis for 
development of subunit vaccines to JEV. These attempts show varying degrees of protection 
in mouse models and use three different approaches using 1) direct protein immunization, 2) 
recombinant pox viruses and 3) recombinant DNA. These are discussed below: 
Direct protein immunizations 
These studies have evaluated different mouse model systems to evaluate the protection 
offered after immunization with JEV antigens in the form of recombinant subviral particles 
produced from cell lines, synthetic and CNBr cleaved fragments of E protein or different JEV 
antigens isolated from different expression systems either in the crude or purified forms.  
It is known that non-infectious extracellular particles (EP) containing the M and E proteins 
without the nucleocapsid are secreted from BHK and Vero cells infected with a JEV prM-E-
NS1-NS2A gene recombinant vaccinia virus (Mason et al., 1991). These EPs have been 
thought to be a promising candidate for a second generation JE subunit vaccine. Mice 
immunized with EPs produced from HeLa cells infected with recombinant vaccinia viruses 
expressing prM and E genes of JEV showed good neutralizing antibody titres and 100% 
protection (Konishi et al., 1992b) as well as long lasting virus specific memory T cells in mice 
(Konishi et al., 1997b). Similar success in affording protection was achieved with EPs from 
cell lines stably transformed with plasmid DNA encoding prM and E genes of JEV (Kojima 
et al., 2003; Hunt et al., 2001). 
The C-terminal region (aa280-414) of the E protein binds several neutralizing antibodies. 
Hence this region or its fragments have been used in approaches that utilized their isolation 
from several expression systems. A protein fragment containing the C-terminal aa319-500 of 
the E protein was expressed along with the N-terminal 65 amino acid residues of NS1 in E. 
coli as a fusion protein with protein A. Mice immunized with this fragment produced 
significant protection and good neutralizing antibody titres (Srivastava et al., 1991). Mice 
immunized with the C-terminal region (aa280-414) of the E protein that was overexpressed 
in E. coli alone failed to generate significant protection and neutralizing antibodies. Hence, it 
is possible that that the N-terminal 65 amino acids of NS1 protein could have played some 
role in protection against viral challenge. A 27 amino acid (aa372-399) stretch within this C-
terminal E fragment expressed in E. coli, either as a fusion protein with protein A or GST 
produces neutralizing antibodies (Seif et al., 1996). Immunization of mice with the same 27 
amino acid peptide expressed as fusion protein with Johnson Grass Mosaic (JGM) virus-like 
particles also produced neutralizing antibody titres and protection was observed upon i.c. 
challenge with JEV (Saini and Vrati, 2003).  
Expression of JEV proteins using a different expression system such as the baculovirus 
system has also produced moderate protection. Significant neutralizing antibody titres and 
moderate protection have been shown in mice immunized with recombinant baculovirus-
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infected spodoptera cells expressing either E protein or a polyprotein including prM, E, NS1, 
NS2A, NS2B and N-terminal 28 amino acids residues of NS3 (McCown et al., 1990). 
Expression of different fragments of the envelope protein reported to bind neutralizing 
antibodies on the surface of Saccharomyces cerevisiae also led to the generation of anti-JEV 
antibodies. However, they were not protective in mice suggesting the importance of 
conformational determinants for protection (Upadhyaya and Manjunath, 2009). 
Immunization of mice with a crude extract of Saccharomyces cerevisiae expressing the E 
protein produced only low titre neutralizing antibodies (Fujita et al., 1987). 
Recombinant Pox virus based immunizations 
Recombinant vaccinia viruses can also be used to generate protective immunity to JEV. 
Neutralizing antibodies and significant levels of protection were generated by immunizing 
mice with recombinant vaccinia viruses expressing prM and E genes (Yasuda et al., 1990) as 
well as vaccinia viruses expressing prM-E-NS1-NS2A genes of JEV. Subsequent studies 
introduced prM and E genes into highly attenuated strains of vaccinia viruses such as 
NYVAC, ALVAC and MVA (Konishi et al., 1997a; Konishi et al., 1992a; Nam et al., 1999). 
These approaches in mice were then followed by testing the efficacy of recombinant vaccinia 
virus system in humans. Highly attenuated strains of vaccinia viruses NYVAC/ALVAC 
expressing prM and E genes of JEV (called as NYVAC-JE and ALVAC-JE) were well 
tolerated in volunteers but were more reactogenic as compared to volunteers immunized 
with licensed form of inactivated JEV vaccine. Studies revealed that NYVAC-JE induced 
neutralizing antibody responses only in vaccinia non-immunised recipients, vaccinia 
immunized volunteers failed to develop protective antibodies. NYVAC-JE was more effective 
in inducing antibody responses as compared to ALVAC-JE (Kanesa-thasan et al., 2000). 
Recombinant DNA based immunizations 
DNA vaccines have been successful against several viral infections. Immunization using 
recombinant DNA constructs expressing prM-E or NS1 alone and the efficient protection 
obtained in mice was first reported in 1998 (Lewis and Babiuk, 1999; Lin et al., 1998). A 
parallel report (Konishi et al., 1998) using mice immunized with DNA constructs expressing 
prM-E genes of JEV showed only low levels of neutralizing antibodies but 100% protection 
was observed upon lethal challenge of mice with JEV. CD8+ CTL response to E protein was 
also induced following immunization with recombinant DNA constructs. Plasmid encoding 
NS1 gene alone was able to afford good protection as compared to previous studies (Konishi 
et al., 1992a; McCown et al., 1990). The protective efficacy of several genes of JEV (C, E, NS1, 
NS3 and NS5) by DNA based immunization have been evaluated in mice (Chen et al., 1999). 
In this study only the E gene construct afforded significant protection either by i.m. 
immunization or by gene gun immunization but they also did not detect neutralizing 
antibodies before challenge in these mice. Thus, it appears that mechanism of protection 
induced by recombinant DNA immunization is different as compared to other 
immunization systems. Neutralizing antibodies were observed to be weak or absent in 
another DNA based vaccine attempt (Ashok and Rangarajan, 2002). The efficacy of various 
routes (i.d., i.v, i.m., i.p.) of immunization with plasmid DNA encoding prM and E was tested 
when delivered along with colloidal gold. They found that i.v. and i.d. routes generated a 
stronger anti-E response as compared to other routes of immunization (Zhao et al., 2003).  
The studies discussed above demonstrate the potential and efficacy of various vaccines 
employed to generate protective immunity to JEV. Various other antiflaviviral agents that 
have been studied are listed in Table 2. 
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Sl 
no 
Antiviral Agent 
 
Target 
 
System used 
 
Reference 
 
1 
 
Rana catesbeiana 
ribonuclease (RC-
RNase) 
enhances apoptosis in JEV-
infected cells 
BHK21 cells (Lee et al., 2011) 
2 Mycophenolic acid immunosuppressant Mouse In vivo (Sebastian et al., 
2011) 
3 
 
Peptide-conjugated 
phosphorodiamidate 
morpholino 
oligomers (PPMOs)
JEV 3' cyclization sequence 
(3'CSI) 
Vero (epithelial), 
Neuro2A 
(neuronal), J774E 
cells (macrophage)
(Anantpadma et 
al., 2010) 
4 Octaguanidinium 
dendrimer-
conjugated 
Morpholino 
3′ and 5′ UTRs Mouse, in vivo (Nazmi et al., 
2010) 
5 Cell-penetrating 
peptide (CPP)-PNA 
conjugates 
cis-acting signals at the 5'-
untranslated region (UTR), 
3'-UTR, and genome 
cyclization motifs 
BHK-21 cells (Yoo et al., 2009) 
6 Pentoxifylline virus assembly and/or 
release 
Cell line and mouse 
in vivo mouse 
(Sebastian et al., 
2009) 
7 Aloe-emodin 
(compounds from 
Chinese herbal 
medicine) 
upregulates expression of 
IFN-stimulated genes such 
as dsRNA-activated 
protein kinase and 2',5'-
oligoisoadenylate synthase
Human HL-CZ 
promonocyte cells 
and TE-671 
medulloblastoma 
cells 
(Lin et al., 
2008c) 
8 Bovine lactoferrin binding to cell surface 
expressed heparan sulfate
CHO cells (Chien et al., 
2008) 
9 Arctigenin (a plant 
lignin) 
antiviral, neuroprotective, 
anti-inflammatory, 
antioxidative effects 
Mouse In vivo (Swarup et al., 
2008) 
10 Minocycline anti-inflammatory and 
antiapoptotic drug 
Mouse In vivo (Mishra and 
Basu, 2008) 
11 N-methylisatin-beta-
Thiosemicarbazone 
(MIBT) derivative 
(SCH 16) 
inhibit JEV replication BHK-21 and PS 
cells 
(Sebastian et al., 
2008) 
12 Rosmarinic acid antiviral and anti-
inflammatory effects 
Mouse In vivo (Swarup et al., 
2007b) 
13 N-nonyl-
deoxynojirimycin 
(NN-DNJ), an alkyl 
iminosugar 
derivative 
inhibits ER ǂ-glucosidases I 
and II 
BHK-21 cells (Wu et al., 2002) 
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14 Bafilomycin A1 vacuolar-type proton (V-
H+) pump inhibitor 
Vero cells (Andoh et al., 
1998) 
15 siRNA NS5 BHK-21 cells (Qi et al., 2008) 
16 siRNA NS1 Vero cells (Liu et al., 
2006b) 
17 siRNA cd loop-coding sequence in 
domain II of the viral 
Envelope protein 
BHK-21, vero, 
Neuro2A cells 
(Kumar et al., 
2006) 
18 DNAZyme 3'-NCR J774E murine 
macrophage & 
mouse in vivo 
(Appaiahgari 
and Vrati, 2007) 
Table 2. Antiviral agents for JEV 
9. Conclusions 
Flaviviruses have developed several strategies to counter the antiviral responses that are 
activated in the host. It is now apparent that they can inhibit both adaptive and innate 
immune responses such as antigen presentation, inhibition of complement factors and 
interferon. However, some of these strategies that may have evolved to enhance virus 
survival such as activation of transcriptional factors result in the activation of inflammatory 
host responses as well. This results in damage to the CNS, a tissue where replenishment and 
renewal of damage tissue is more difficult. Virus-induction of MHC molecules is also a host 
response that leads to antiviral mechanisms in the long run such as activation of CTL. It is 
believed that all these responses are aimed at inhibition of NK cells that may kill virus 
infected cells immediately after infection. However, the activation of nonclassical MHC 
molecules by JEV could be considered as a viral strategy to the inhibit NK cells since several 
nonclassical MHC molecules bind to NK receptors leading to their inhibition. The 
presence of inflammatory responses in vivo highlights its importance in influencing the 
differences that may occur during ex vivo and in vitro studies when compared to in vivo 
studies. Hence apart from the development of new approaches to eradicate the disease, a 
basic understanding of the nature by which this virus alters the balance between 
protective and immunopathological mechanisms triggered within the infected host is also 
important. 
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